Type 1 Diabetes Financial Planning: Medicare Through ESRD, Technology Costs, and Benefits Preservation

More than 1.9 million Americans live with Type 1 diabetes — a lifelong autoimmune condition requiring continuous insulin therapy, monitoring, and technology to survive. Most T1D adults live full, working lives and do not need special needs financial planning in any traditional sense. But a meaningful subset do: those with severe hypoglycemia unawareness, those who develop significant complications (retinopathy, nephropathy, neuropathy), those who require SSI or SSDI to maintain access to the technology keeping them alive, and families with a T1D dependent who may never live independently. For all of these individuals and families, there is one financial planning fact they must understand above all others: what happens when kidneys fail.

How SSA evaluates Type 1 diabetes for SSDI and SSI

Type 1 diabetes by itself is not a Social Security Blue Book listing. SSA's Section 9.00 (Endocrine Disorders — Adults) takes a redirected approach: rather than listing criteria for diabetes itself, it directs evaluators to assess the damage the condition has caused to other body systems and apply the applicable listing for that system.¹

This is both a limitation and an opportunity. The limitation: a well-controlled T1D adult who has not developed significant complications is unlikely to qualify for SSDI no matter how difficult daily management is. The opportunity: when complications develop, the qualifying criteria are well-defined and achievable — and there are multiple pathways depending on which system is affected.

Hypoglycemia unawareness and the RFC pathway

Hypoglycemia unawareness — the neurological failure to perceive warning symptoms of low blood glucose — affects approximately 20–25% of people with T1D and is associated with prior severe hypoglycemic events. For affected individuals, blood glucose can drop to 40 or 30 mg/dL without the sweating, shaking, or dizziness that would normally prompt treatment, and the first symptom may be loss of consciousness.¹

There is no Blue Book listing specifically for hypoglycemia unawareness. SSA evaluates disability through the RFC (Residual Functional Capacity) framework when no single listing is met. A successful RFC claim for severe T1D hypoglycemia unawareness requires:

• Medical documentation from the endocrinologist — confirmed unawareness, hypoglycemia logs, records of ER visits or hospitalizations for severe hypoglycemia
• Documented history of episodes severe enough to require third-party assistance, loss of consciousness, or seizure
• Medical opinion that the person cannot safely work without continuous supervision (most competitive employment cannot accommodate this)
• Evidence that CGM use, AID system, and medical management have not adequately resolved the episodes

The RFC claim is harder to win than a listing-level claim because it requires a finding that all limitations combined preclude any competitive work — but it is a legitimate pathway for genuinely severe cases. A disability attorney with endocrine-related RFC experience is typically necessary.

Children with T1D: SSI before age 6 and functional evaluation after

SSA's childhood endocrine section (109.00) includes a specific provision for young children: a child under age 6 who requires daily insulin is automatically considered disabled for SSI purposes — no further functional evidence required.²

At age 6, automatic qualification ends. Children age 6 and older with T1D are evaluated on how the condition functionally limits them compared to age-appropriate norms. Relevant factors SSA examines include:

• Documented episodes of severe hypoglycemia requiring school nurse intervention or emergency response, limiting participation in normal educational settings
• Co-occurring intellectual disability or developmental disorder that independently qualifies (T1D + ADHD is very common; ADHD may qualify independently under 112.11)
• Cognitive effects of repeated severe hypoglycemia — documented learning and memory effects in children with multiple unconscious events
• Physical limitations from early complications (uncommon with good care access, but possible)

SSI eligibility for a T1D child is subject to parental income deeming — meaning many T1D children of middle-income families will not qualify even if they would otherwise meet disability criteria. At age 18, deeming ends and the SSI determination is made on the child's own resources and income alone. For some T1D young adults with complications or documented functional limitations, the age-18 transition creates SSI eligibility that did not exist during childhood. See When Your Special Needs Child Turns 18 for the full transition checklist.

ESRD and Medicare at any age: the most important T1D planning provision

Under normal rules, Medicare requires age 65 or a 24-month waiting period after SSDI approval. ESRD is one of only two conditions — along with ALS — that override both requirements entirely: any person with ESRD — any age, any work history, any income level — can enroll in Medicare.

The timing mechanics are specific:³

After a successful transplant, Medicare continues for 36 months post-transplant, then terminates if ESRD was the only basis. Immunosuppressant drugs are covered for the life of the transplanted kidney under Medicare Part B regardless of when the 36-month Medicare eligibility ends.

Why this changes the financial plan

A T1D adult who enters ESRD and enrolls in Medicare typically becomes dual-eligible: Medicare as primary, Medicaid as secondary. This dual-eligible status typically eliminates or dramatically reduces out-of-pocket costs for:

• Dialysis itself (3× weekly; each session ~$400–$500 at retail — fully covered by Medicare 80% + Medicaid secondary)
• CGM sensors and transmitters — Medicare covers CGMs under Part B for insulin-requiring patients as durable medical equipment
• Insulin — covered under Medicare Part D with the $35/month cap per prescription
• Insulin pump — covered as DME under Medicare Part B when medical necessity criteria are met
• Transplant hospitalization and post-transplant immunosuppressants

The SNT planning implication: A T1D beneficiary who develops ESRD and has Medicare will have substantially lower supplemental care costs than one on commercial insurance alone — because Medicare + Medicaid dual coverage is remarkably comprehensive for the conditions that accompany ESRD. SNT corpus targets and annual supplemental need estimates should be recalculated at the point of ESRD, not assumed to remain constant from pre-ESRD levels.

The coverage gap to protect: The 3-month dialysis waiting period is when the T1D-ESRD patient is most vulnerable. Commercial insurance must remain intact during this window. If the person is on an employer plan, understand COBRA rights and cost. If they are on a parent's plan, the ESRD diagnosis does not extend dependent coverage past age 26 — but ESRD Medicare enrollment should be initiated immediately to minimize the uncovered window.

Technology cost planning: insulin, CGM, and insulin pumps

T1D's ongoing financial management centers on three intertwined technology costs, each with different insurance and planning implications.

Insulin

The insulin affordability landscape has changed significantly since 2022, but the patchwork of coverage creates real planning risk for any T1D person on SSI or at risk of losing insurance:⁴

• Medicare Part D: The Inflation Reduction Act (2022) capped insulin out-of-pocket costs at $35 per month per covered insulin, effective January 2023. This applies to all Medicare enrollees including T1D adults enrolled via the ESRD pathway.
• State laws: 29 states have enacted insulin cost caps for state-regulated commercial plans as of early 2026, typically $25–$100/month. California, Colorado, Illinois, New York, Virginia, and Wisconsin are covered; self-insured employer plans (ERISA-governed) are exempt from state law.
• Manufacturer programs: All three major insulin manufacturers (Eli Lilly, Novo Nordisk, Sanofi) cap commercial insurance out-of-pocket at $35/month for many branded insulins. These are voluntary programs and terms may change.
• Without insurance or programs: Analog insulins (Humalog, Novolog, Lantus) can cost $300–$500+ per vial at retail. Biosimilars are available at lower cost. The federal INSULIN Act ($35 cap for commercial insurance) was introduced in March 2026 but had not passed as of mid-2026.

The planning takeaway: for a T1D beneficiary on SSI/Medicaid, losing Medicaid to a benefits planning error can expose them to full retail insulin costs. Medicaid is the structural insurance floor — not manufacturer programs — because manufacturer programs can change with notice.

Continuous Glucose Monitor (CGM)

A CGM provides continuous blood glucose readings every 5 minutes and is clinical standard of care for T1D — especially for anyone with any history of severe hypoglycemia. For T1D adults with hypoglycemia unawareness, CGM is not optional; it is the technology keeping them safe.⁵

Medicare covers CGMs as therapeutic DME for insulin-requiring patients — both T1D adults enrolled via ESRD and those enrolled via SSDI after the 24-month wait. For T1D adults on Medicaid without Medicare, CGM coverage varies by state and is often prior-authorization intensive. The SNT distribution language should explicitly authorize CGM sensor and transmitter replacement as an ongoing recurring expense.

Insulin pump

Insulin pumps deliver continuous subcutaneous insulin infusion, and modern closed-loop (automated insulin delivery, AID) systems communicate with a CGM to adjust basal rates automatically — significantly reducing A1C and hypoglycemic episodes compared to multiple daily injections for many patients.⁵

• Device cost without insurance: $4,000–$7,000 (Tandem t:slim X2, Tandem Mobi); Omnipod 5 (tubeless) typically $0–$200/month with insurance
• Ongoing supplies: Infusion sets, cartridges, and reservoirs add several hundred dollars per month at retail
• With Medicare or commercial DME coverage: More than 30% of Tandem users report $0 out-of-pocket; most major plans cover pumps as DME with a letter of medical necessity
• Replacement cycle: Device warranty typically 4 years; budget for replacement every 4 years in any long-horizon SNT

The SNT distribution language for T1D should explicitly authorize pump device replacement, pump supplies (infusion sets, cartridges, reservoirs), and any FDA-approved AID system upgrade.

Insurance continuity and Medicaid preservation

For a T1D adult on SSI and Medicaid, the financial stakes of a benefits error are as high as for any beneficiary with a high-cost rare disease. Medicaid makes insulin affordable, CGM covered, and pump supplies at minimal out-of-pocket cost. A resource or income miscalculation that destroys SSI can expose this person to retail technology costs within one insurance billing cycle.

Section 1619(b): keeping Medicaid while earning above SGA

Section 1619(b) allows an SSI recipient who begins earning above the Substantial Gainful Activity threshold ($1,690/month in 2026 for non-blind individuals; $2,830/month for blind) to retain Medicaid coverage even as the cash SSI benefit reduces to zero.⁶ For a working T1D adult on SSI whose Medicaid covers CGM, insulin pump, and insulin, this protection is not a technicality — it is the reason working is financially viable. Before any significant earnings increase:

1. Confirm your state's individualized 1619(b) Medicaid threshold (varies by state: typically $29,000–$84,000/year; higher for individuals whose Medicaid costs are higher, which includes T1D patients using expensive technology)
2. Contact a Work Incentive Planning and Assistance (WIPA) counselor to calculate the individualized threshold including all IRWE deductions
3. Never voluntarily terminate Medicaid without confirming Medicare or equivalent coverage is in place

Impairment-Related Work Expenses (IRWE) for T1D

Expenses necessary for work and related to the T1D disability can be deducted from countable earned income in the SSI formula — reducing the SSI offset calculation and increasing the individualized 1619(b) threshold. T1D-specific IRWE candidates include:

• Insulin and diabetes supplies used during work hours
• CGM receiver or smartphone used for diabetes monitoring at work
• Glucose tablets and hypoglycemia treatment supplies carried to work
• Transportation to medical appointments when hypoglycemia unawareness or visual impairment restricts driving

IRWE claims require documentation: receipts, a physician statement connecting the expense to the disability and work necessity, and SSA approval. A WIPA counselor can assist with the documentation process.

ABLE accounts for T1D

ABLE accounts in 2026 allow contributions of up to $20,000/year from all sources, with an additional $15,650 from the beneficiary's own earned income (ABLE-to-Work). T1D, with onset virtually always before age 46, automatically meets the ABLE age eligibility criterion.⁶

For a T1D adult on SSI, an ABLE account:

• Shelters up to $100,000 from the SSI $2,000 resource limit
• Funds insulin, CGM supplies, pump supplies, and ophthalmology visits as Qualified Disability Expenses (healthcare and assistive technology categories)
• Provides day-to-day flexibility for recurring technology costs without requiring SNT trustee approval

The practical ABLE / SNT coordination for T1D: the ABLE account handles recurring monthly technology costs (CGM sensors, infusion sets, insulin copays); the SNT holds the capital reserve for larger or unexpected costs (ophthalmology laser treatment, neuropathy procedures, dialysis gap costs, or any costs exceeding the ABLE balance). See the SNT vs ABLE Account comparison for detailed mechanics.

SNT for T1D families: distribution language and sizing

Third-party SNT: inheritance planning for T1D beneficiaries

Even when a T1D child is largely independent, parents who intend to leave assets to that child must review their beneficiary designations and estate plan. If the child is on SSI, a direct bequest, retirement account designation, or life insurance designation in the child's name destroys SSI and Medicaid eligibility immediately. All assets intended for an SSI-eligible T1D child must flow through a properly drafted third-party SNT. Annual gifts from grandparents or other family members — up to $19,000 per recipient in 2026 — must similarly go to the SNT, not directly to the beneficiary. See Inheritance Planning for Special Needs Families for the full framework.

SNT distribution language for T1D

Standard SNT distribution language should be supplemented with T1D-specific categories so the trustee has clear authorization for recurring costs without requiring individual review of each purchase:

• Insulin (all formulations, including analog insulins, biosimilars, and any formulations not currently on formulary)
• Continuous glucose monitor sensors, transmitters, and receivers; replacement devices
• Insulin pump device (including upgrades and AID system transitions), cartridges, infusion sets, and all pump supplies
• Blood glucose monitoring supplies (backup testing for pump and CGM failures)
• Ophthalmology visits, retinal imaging, laser photocoagulation treatment, anti-VEGF injections (Avastin, Eylea, Lucentis) for diabetic retinopathy
• Podiatry: diabetic foot care, therapeutic footwear, orthotics, wound care, and surgical consultation for peripheral vascular complications
• Nutritional counseling and diabetes education programs not covered by Medicaid
• Nephrology visits and any gap costs during the ESRD Medicare waiting period
• Transportation when hypoglycemia unawareness or visual impairment restricts driving

SNT sizing for T1D

The appropriate SNT corpus varies widely by complication status and insurance coverage. These are illustrative planning benchmarks:

Use the SNT Funding Calculator and Lifetime Care Cost Calculator to model specific scenarios, particularly how SNT adequacy changes across the pre-ESRD, dialysis, and post-transplant phases.

Life insurance considerations for T1D

Type 1 diabetes is insurable — unlike some genetic conditions — but it is typically rated. Underwriting reflects A1C history, complication status, and age at application:

• Good control, no complications, young applicant: A1C consistently below 7.5% may qualify for standard or slightly rated rates from some carriers. The 20s and early 30s are the window for the best rates.
• With documented complications: Retinopathy, nephropathy, or neuropathy on record produces a significant rating increase or declination.
• After ESRD diagnosis: Standard-rate life insurance is typically unobtainable. Long-term disability insurance should be secured before kidney function declines significantly.

For parents of T1D children, the parents' own life insurance — to fund the SNT at death — is the primary SNT funding vehicle, and T1D does not affect the parents' insurability. See Life Insurance for Special Needs Trusts for the SNT funding mechanics.

Priority action checklist for T1D families

1. If the T1D dependent is on SSI, understand Section 1619(b) before any earnings milestone. A T1D SSI recipient who earns above SGA but stays within their state's 1619(b) threshold keeps Medicaid intact — the technology access floor. Confirm the state threshold with a WIPA counselor before any significant employment change.
2. Know the ESRD Medicare enrollment process before dialysis begins. If a T1D dependent has CKD Stage 3 or 4 (eGFR 15–60), plan the ESRD Medicare enrollment now — including how to bridge commercial insurance during the waiting period and how to handle the SSI interaction once Medicare begins.
3. Ensure all estate planning routes through the SNT — not directly to the T1D beneficiary. Every family member who wants to leave anything to an SSI-eligible T1D dependent must update their will, retirement beneficiary designations, and life insurance designations to name the SNT. A $50,000 direct bequest destroys benefits; $50,000 to the SNT preserves them and provides the same support.
4. Review SNT distribution language for T1D-specific costs. Standard SNT language authorizes medical care generically but may not explicitly name insulin pump supplies, CGM replacement sensors, or retinal treatment. Specific authorization removes trustee hesitation and speeds distribution for time-sensitive medical needs.
5. Open an ABLE account for recurring technology expenses. An ABLE account handles monthly CGM, insulin, and pump supply costs at the beneficiary's direction without trustee approval — while the SNT holds the long-term reserve. Together they provide both day-to-day flexibility and capital security.
6. Pursue SSDI if significant complications are present. Stage 4–5 nephropathy, significant retinal loss, or disabling neuropathy may qualify through the applicable Blue Book listing. Establish SSDI before ESRD Medicare enrollment to understand how both interact.
7. Secure life and disability insurance while complications are minimal. The insurable window narrows with every complication that enters the medical record. A T1D young adult in their 20s with well-controlled diabetes should apply now — before the nephrology record accumulates and before ESRD closes the window permanently.
8. Apply for HCBS waiver early if care needs are significant. T1D adults with functional limitations requiring personal care — particularly those with severe neuropathy, visual impairment, or other complications affecting daily living — should apply for the HCBS physical disability waiver now. Waitlists run 1–7+ years. See HCBS Medicaid Waiver guide.

Sources

1. SSA — Section 9.00 Endocrine Disorders (Adult Blue Book). No specific numbered criteria for diabetes mellitus as a standalone listing. Evaluation approach: SSA assesses the complications diabetes has caused to other body systems and applies the applicable listing for that system. Cross-references: nephropathy under 6.00 (kidney); retinopathy under 2.00 (vision); peripheral neuropathy under 11.00 (neurological); peripheral vascular disease and amputation under 1.00 (musculoskeletal); cardiovascular complications under 4.00; cognitive impairment under 12.00. Hypoglycemia unawareness noted as a documented complication affecting some T1D adults; evaluated via RFC when no listing criterion is individually met. SSDI SGA thresholds 2026: $1,690/month non-blind; $2,830/month blind. SSI FBR 2026: $994/month. Approximately 20–25% of T1D individuals develop hypoglycemia unawareness; associated with recurrent severe hypoglycemia history (Cryer et al.).
2. SSA — Section 109.00 Endocrine Disorders (Childhood Blue Book). Automatic disability qualification: a child under age 6 who requires daily insulin is considered disabled without additional functional evidence. Children age 6 and older: no automatic qualification; evaluated on functional limitations compared to age norms. Relevant evaluation factors: frequency of severe hypoglycemic episodes requiring emergency intervention; cognitive or learning effects of prior hypoglycemia events; comorbid developmental or intellectual disability (T1D + ADHD: approximately 33% prevalence per research literature, qualifying independently under 112.11 when functional limitations are marked). SSI deeming: parental income deemed to child under 18; deeming ends at 18 and SSI eligibility re-determined on child's own resources and income — creating new SSI eligibility at 18 for some T1D young adults with functional limitations who did not qualify as children due to parental income.
3. Medicare.gov — End-Stage Renal Disease (ESRD) Medicare Eligibility. ESRD is one of two conditions (with ALS) qualifying individuals for Medicare at any age regardless of work history. Coverage timing: in-center hemodialysis — Medicare begins first day of 4th month of dialysis (3-month waiting period). Home dialysis training (peritoneal dialysis or home hemodialysis) — Medicare begins first month of training (no waiting period). Kidney transplant — Medicare begins the month of hospital admission for the transplant. Post-transplant: Medicare continues 36 months after the transplant month when ESRD is the sole basis; immunosuppressants covered under Part B for the life of the transplanted kidney regardless of the 36-month limit. Medicare Part B covers CGM as therapeutic DME for insulin-requiring patients; Part D $35/month insulin cap applies to all Medicare insulin prescriptions (IRA 2022). Dual eligibility (Medicare + Medicaid) typical for ESRD patients previously on SSI; eliminates most out-of-pocket costs. Diabetic nephropathy: leading cause of ESRD in the US, accounting for approximately 38% of new ESRD cases annually (USRDS 2023 Annual Data Report).
4. Insulin Cost 2026: Prices, Savings Programs, and State Laws. Medicare Part D insulin cap: $35/month per covered insulin (IRA 2022, effective January 2023). State caps: 29 states have enacted insulin cost caps for state-regulated commercial plans as of early 2026; caps typically $25–$100/month; ERISA self-insured employer plans exempt from state law. Manufacturer voluntary caps: Eli Lilly, Novo Nordisk, Sanofi cap commercial insurance OOP at $35/month for branded insulins — voluntary, subject to change. Federal INSULIN Act introduced March 2026 (Senators Kennedy, Collins, Shaheen, Warnock): proposed $35 federal cap for commercial insurance — not yet enacted as of mid-2026. Analog insulins without insurance or programs: $300–$500+/vial retail. Annual gift tax exclusion 2026: $19,000 per recipient per donor (IRS Rev. Proc. 2025-61; unchanged from 2025).
5. GoodRx — Dexcom G7 15-Day Pricing 2026; Tandem Diabetes Care Cost and Coverage. Dexcom G7 retail: approximately $499/month (3-sensor 15-day supply); GoodRx cash price approximately $174. FreeStyle Libre 3: retail approximately $70/month. Medicare Part B DME coverage: both Dexcom and FreeStyle Libre systems covered as therapeutic CGM for insulin-requiring patients meeting clinical criteria; 20% Medicare coinsurance eliminated by secondary Medicaid for dual-eligible patients. Insulin pump — Tandem t:slim X2 retail $4,000–$7,000 without insurance; Omnipod 5 $0–$200/month with insurance; both classified as DME. More than 30% of Tandem users report $0 out-of-pocket. Supplies (infusion sets, cartridges): several hundred dollars per month retail; covered as DME supplies with insurance. Replacement cycle: pump device warranty 4 years. All CGM and pump system costs qualify as ABLE Qualified Disability Expenses (healthcare and assistive technology).
6. ABLE National Resource Center — 2026 Contribution Limits and Section 1619(b). Annual ABLE contribution limit 2026: $20,000 from all sources. ABLE-to-Work additional contribution: $15,650 from beneficiary's own earned income (2026 federal poverty level, one-person household). Age eligibility: disability onset before age 46 (ABLE Age Adjustment Act, January 2026). T1D, with onset before age 46 in virtually all cases, always qualifies on the age criterion. SSI protection: ABLE balance up to $100,000 does not count toward SSI's $2,000 resource limit. Qualified Disability Expenses include healthcare, preventive care, medical equipment (insulin pumps, CGM), assistive technology (CGM receivers), and transportation. Section 1619(b) 2026: SSI recipients who earn above SGA ($1,690/month non-blind; $2,830/month blind) retain Medicaid while SSI reduces to zero; individualized state threshold ranges $29,412–$84,208/year (SSA POMS SI 02302.200, updated January 2026); threshold is higher for individuals with higher Medicaid costs, benefiting T1D patients who use expensive technology covered by Medicaid. WIPA counselors: 1-866-968-7842 to locate local Work Incentive Planning and Assistance.

Rules verified against 2026 SSA, Medicare, and ABLE standards. SSI FBR $994/month (2026). SSDI SGA $1,690/month non-blind; $2,830/month blind (2026). ABLE contribution limit $20,000/year; ABLE-to-Work $15,650/year; onset-before-46 eligibility (all 2026). Section 1619(b) thresholds per SSA POMS SI 02302.200, updated January 2026. Medicare ESRD eligibility and timing per Medicare.gov; dialysis waiting period, home dialysis exception, and transplant coverage per CMS ESRD materials. Insulin cap $35/month under Medicare Part D per IRA 2022; state caps per state legislation as of early 2026. Annual gift exclusion $19,000/recipient/donor (2026) per IRS Rev. Proc. 2025-61. CGM and pump pricing via GoodRx and Tandem Diabetes Care 2026. SNT corpus targets are illustrative based on care scenario assumptions and are not guarantees of adequacy.